• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1267438 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
: V2 C8 V' ~% v5 o" b# E: dNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 / Y  U' Q' u1 i) n) Y3 b. |& ^. q* j
+ Author Affiliations
8 z  R' U+ @; X! U% i- c5 {
  d7 T. {* \. L* C7 T7 l% U1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 I4 _7 P8 C0 ]$ N9 S  k2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan / n& u. V9 h0 y9 G5 Z5 ]
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
$ N0 D0 b! r: ?) n: n7 \4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
/ _# H5 n5 Q4 H) m3 j5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
2 a6 k5 p/ [2 f8 I; K' T; ^5 M6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
4 X8 Q3 @2 j# }9 e# I. f7Kinki University School of Medicine, Osaka 589-8511, Japan % O* d  m, `$ ]0 U' E, D
8Izumi Municipal Hospital, Osaka 594-0071, Japan
3 o0 c) r( K# A9 Y+ i- k+ g9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
( j4 H4 v$ E" a" RCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp $ z0 ]8 L8 z# Y- T0 U
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
1 z+ l* D1 }: |& M, A: Q  G& K- t* g4 K' `/ {, ~. l. I" }1 w+ M
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type 9 h4 V6 q+ }. d1 I

/ Z! R0 v8 D% f/ AAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 4 ?6 ^8 R) c! H" l6 o+ E3 O7 h

' U0 E: Y: f8 t+ D5 D! cAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
+ T% F. I+ Z& E2 \0 Z+ l8 v+ K6 b* o% C7 H  A
Published online on: Thursday, December 1, 2011 * S$ D8 q7 Y. I" t2 C
; I$ h' a$ E/ N
Doi: 10.3892/ol.2011.507
- T1 I; M/ c* U5 ?8 @6 V- x0 M- F! k/ V/ Q4 ~
Pages: 405-410
1 S+ \) T1 R5 ~( R7 d- E7 `8 f' i# M( t9 `. m
Abstract:
9 D- }% x0 _# p5 q, T* ^S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.. k2 K, v, u4 ^$ ^
' q' `4 i& a5 T
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
( k' U* y- z5 f+ T8 Y' @$ OF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
) k1 L8 |  d! [$ }: C+ U+ Author Affiliations
1 G3 _( X& ]" ?" R5 X1 _/ a1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
4 Y- f5 E6 i" h2Department of Thoracic Surgery, Kyoto University, Kyoto
- K5 {1 q! s7 j2 l: e0 j' b3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan 9 [. L  g% l' r- L3 O( ^& u
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 4 e3 q. |+ m2 O# B! m
Received September 3, 2010.
/ K: M% a8 K6 m# yRevision received November 11, 2010. : e# f2 x: ?' k5 n  ~
Accepted November 17, 2010.
9 `( F% N: s- q! Z, H- k3 E1 Q3 SAbstract
( z& e3 W% Z' N0 k& o  K, S: C# {Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
& \" ?1 U. K/ |$ t; `1 a! D. s, TPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. ' E% g- m( ~  y
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
0 O2 V5 i2 B1 Q3 F9 G8 r( SConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
! u+ }4 q8 Y* {, O! W9 g" I
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
8 q# W8 n2 R1 L6 J! E5 I, l今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?7 r7 b9 Q& F( ^9 i. Y
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy* X7 M' E$ b0 Z* j* K3 O4 Y
http://clinicaltrials.gov/ct2/show/NCT015235877 p7 r: W7 |# S" y4 f

7 P: ]+ f4 Y+ ]6 m( `BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
/ W( i& c9 {, A" X! b7 ehttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 4 n" e3 m8 v0 O- i3 l

" h0 s' b- a. K! q. m- V从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。  y; e) k+ X" }$ W
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
. j5 Y. u4 D/ l* P
没有副作用是第一追求,效果显著是第二追求。" S9 W$ ]# M9 _3 g  M# P2 B" ^4 d
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表